Siren Biotechnology
6 known investors
Siren Biotechnology develops next-generation AAV (adeno-associated virus) platforms for gene therapy applications, including gene repair, gene transfer, and gene editing. The company focuses on advancing treatments for a wide range of rare diseases through engineered viral vectors and directed evolution approaches.
BiotechDigital HealthMedical Devices
Founders & leadership
DN
Dr. Nicole PaulkCEO, Founder, and President
Investors · 6
In the news
- Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High-Grade Glioma - BioSpacebiospace.com · 2026
- Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Gliomaglobenewswire.com · 2026
- How a Biotech CEO Turned 1,600 Everyday Investors Into Backers—and Raised $4 Millionwewillcure.com · 2025
- Siren, a gene therapy startup, tests unconventional alternative to venture funding | BioPharma Divebiopharmadive.com · 2025
- Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - Siren Biotechnologysirenbiotechnology.com · 2025
- Invest - Siren Biotechnologysirenbiotechnology.com · 2025